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Abstract: In glioma surgery, Protoporphyrin IX (PpIX) fluorescence may
identify residual tumor that could be resected while minimizing damage to
normal brain. We demonstrate that improved sensitivity for wide-field
spectroscopic fluorescence imaging is achieved with minimal disruption to
the neurosurgical workflow using an electron-multiplying charge-coupled
device (EMCCD) relative to a state-of-the-art CMOS system. In phantom
experiments the EMCCD system can detect at least two orders-ofmagnitude lower PpIX. Ex vivo tissue imaging on a rat glioma model
demonstrates improved fluorescence contrast compared with neurosurgical
fluorescence microscope technology, and the fluorescence detection is
confirmed with measurements from a clinically-validated spectroscopic
probe. Greater PpIX sensitivity in wide-field fluorescence imaging may
improve the residual tumor detection during surgery with consequent
impact on survival.
©2015 Optical Society of America
OCIS codes: (170.3890) Medical optics instrumentation; (170.6280) Spectroscopy,
fluorescence and luminescence.

References and links
1.
2.
3.
4.
5.
6.

C. Nimsky, A. Fujita, O. Ganslandt, B. Von Keller, and R. Fahlbusch, “Volumetric assessment of glioma
removal by intraoperative high-field magnetic resonance imaging,” Neurosurgery 55(2), 358–371 (2004).
Q. T. Nguyen and R. Y. Tsien, “Fluorescence-guided surgery with live molecular navigation--a new cutting
edge,” Nat. Rev. Cancer 13(9), 653–662 (2013).
W. Stummer, U. Pichlmeier, T. Meinel, O. D. Wiestler, F. Zanella, and H.-J. Reulen; ALA-Glioma Study Group,
“Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised
controlled multicentre phase III trial,” Lancet Oncol. 7(5), 392–401 (2006).
W. Stummer, H. Stepp, G. Möller, A. Ehrhardt, M. Leonhard, and H. J. Reulen, “Technical principles for
protoporphyrin-IX-fluorescence guided microsurgical resection of malignant glioma tissue,” Acta Neurochir.
(Wien) 140(10), 995–1000 (1998).
G. Widhalm, S. Wolfsberger, G. Minchev, A. Woehrer, M. Krssak, T. Czech, D. Prayer, S. Asenbaum, J. A.
Hainfellner, and E. Knosp, “5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in
diffusely infiltrating gliomas with nonsignificant contrast enhancement,” Cancer 116(6), 1545–1552 (2010).
P. A. Valdés, F. Leblond, A. Kim, B. T. Harris, B. C. Wilson, X. Fan, T. D. Tosteson, A. Hartov, S. Ji, K.
Erkmen, N. E. Simmons, K. D. Paulsen, and D. W. Roberts, “Quantitative fluorescence in intracranial tumor:
implications for ALA-induced PpIX as an intraoperative biomarker,” J. Neurosurg. 115(1), 11–17 (2011).

#252150
Received 19 Oct 2015; revised 11 Nov 2015; accepted 16 Nov 2015; published 30 Nov 2015
(C) 2015 OSA 1 Dec 2015 | Vol. 6, No. 12 | DOI:10.1364/BOE.6.005063 | BIOMEDICAL OPTICS EXPRESS 5063

7.
8.
9.
10.
11.
12.

13.

14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.

Y. Kajimoto, T. Kuroiwa, S. Miyatake, T. Ichioka, M. Miyashita, H. Tanaka, and M. Tsuji, “Use of 5aminolevulinic acid in fluorescence-guided resection of meningioma with high risk of recurrence,” J. Neurosurg.
106(6), 1070–1074 (2007).
K. Bekelis, P. A. Valdés, K. Erkmen, F. Leblond, A. Kim, B. C. Wilson, B. T. Harris, K. D. Paulsen, and D. W.
Roberts, “Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull
base meningiomas,” Neurosurg. Focus 30(5), E8 (2011).
P. Valdes, F. Leblond, and V. L. Jacobs, “Fluorescence detection in the operating room: a review of principles,
methods, and applications,” Curr. Med. Imaging Rev. 8, 211–232 (2012).
P. A. Valdés, V. Jacobs, B. T. Harris, B. C. Wilson, F. Leblond, K. D. Paulsen, and D. W. Roberts, “Quantitative
fluorescence using 5-aminolevulinic acid-induced protoporphyrin IX biomarker as a surgical adjunct in lowgrade glioma surgery,” J. Neurosurg. 123(3), 771–780 (2015).
D. N. Louis, H. Ohgaki, O. D. Wiestler, W. K. Cavenee, P. C. Burger, A. Jouvet, B. W. Scheithauer, and P.
Kleihues, “The 2007 WHO Classification of Tumours of the Central Nervous System,” Acta Neuropathol.
114(2), 97–109 (2007).
M. Lacroix, D. Abi-Said, D. R. Fourney, Z. L. Gokaslan, W. Shi, F. DeMonte, F. F. Lang, I. E. McCutcheon, S.
J. Hassenbusch, E. Holland, K. Hess, C. Michael, D. Miller, and R. Sawaya, “A multivariate analysis of 416
patients with glioblastoma multiforme: prognosis, extent of resection, and survival,” J. Neurosurg. 95(2), 190–
198 (2001).
W. Stummer, H.-J. Reulen, T. Meinel, U. Pichlmeier, W. Schumacher, J.-C. Tonn, V. Rohde, F. Oppel, B.
Turowski, C. Woiciechowsky, K. Franz, and T. Pietsch; ALA-Glioma Study Group, “Extent of resection and
survival in glioblastoma multiforme: identification of and adjustment for bias,” Neurosurgery 62(3), 564–576
(2008).
K. Petrecca, M.-C. Guiot, V. Panet-Raymond, and L. Souhami, “Failure pattern following complete resection
plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma,” J. Neurooncol.
111(1), 19–23 (2013).
M. J. McGirt, K. L. Chaichana, F. J. Attenello, J. D. Weingart, K. Than, P. C. Burger, A. Olivi, H. Brem, and A.
Quinoñes-Hinojosa, “Extent of surgical resection is independently associated with survival in patients with
hemispheric infiltrating low-grade gliomas,” Neurosurgery 63(4), 700–708 (2008).
M. S. Berger, A. V. Deliganis, J. Dobbins, and G. E. Keles, “The effect of extent of resection on recurrence in
patients with low grade cerebral hemisphere gliomas,” Cancer 74(6), 1784–1791 (1994).
G. E. Keles, K. R. Lamborn, and M. S. Berger, “Low-grade hemispheric gliomas in adults: a critical review of
extent of resection as a factor influencing outcome,” J. Neurosurg. 95(5), 735–745 (2001).
T. Hollon, S. L. Hervey-Jumper, O. Sagher, and D. A. Orringer, “Advances in the Surgical Management of LowGrade Glioma,” Semin. Radiat. Oncol. 25(3), 181–188 (2015).
A. Kim, M. Khurana, Y. Moriyama, and B. C. Wilson, “Quantification of in vivo fluorescence decoupled from
the effects of tissue optical properties using fiber-optic spectroscopy measurements,” J. Biomed. Opt. 15(6),
067006 (2010).
P. A. Valdés, F. Leblond, V. L. Jacobs, B. C. Wilson, K. D. Paulsen, and D. W. Roberts, “Quantitative,
spectrally-resolved intraoperative fluorescence imaging,” Sci. Rep. 2, 798 (2012).
P. A. Valdes, V. L. Jacobs, B. C. Wilson, F. Leblond, D. W. Roberts, and K. D. Paulsen, “System and methods
for wide-field quantitative fluorescence imaging during neurosurgery,” Opt. Lett. 38(15), 2786–2788 (2013).
X. Zhang, “Instrumentation in Diffuse Optical Imaging,” Photonics 1(1), 9–32 (2014).
J. Hernandez-Palacios and L. L. Randeberg, “Intercomparison of EMCCD- and sCMOS-based imaging
spectrometers for biomedical applications in low-light conditions,” in (2012), Vol. 8215, p. 82150Q–82150Q–9.
C. A. Combs, “Fluorescence microscopy: a concise guide to current imaging methods,” Curr. Protoc. Neurosci.
Editor. Board Jacqueline N Crawley Al Chapter 2, Unit2.1 (2010).
C. Li, G. S. Mitchell, J. Dutta, S. Ahn, R. M. Leahy, and S. R. Cherry, “A three-dimensional multispectral
fluorescence optical tomography imaging system for small animals based on a conical mirror design,” Opt.
Express 17(9), 7571–7585 (2009).
F. Bestvater, Z. Seghiri, M. S. Kang, N. Gröner, J. Y. Lee, K.-B. Im, and M. Wachsmuth, “EMCCD-based
spectrally resolved fluorescence correlation spectroscopy,” Opt. Express 18(23), 23818–23828 (2010).
M. Burkhardt and P. Schwille, “Electron multiplying CCD based detection for spatially resolved fluorescence
correlation spectroscopy,” Opt. Express 14(12), 5013–5020 (2006).
O. Daigle, C. Carignan, J.-L. Gach, C. Guillaume, S. Lessard, C.-A. Fortin, and S. Blais-Ouellette, “Extreme
faint flux imaging with an EMCCD,” Publ. Astron. Soc. Pac. 121(882), 866–884 (2009).
P. A. Valdés, A. Kim, F. Leblond, O. M. Conde, B. T. Harris, K. D. Paulsen, B. C. Wilson, and D. W. Roberts,
“Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in lowand high-grade glioma surgery,” J. Biomed. Opt. 16(11), 116007 (2011).
P. A. Valdés, F. Leblond, A. Kim, B. C. Wilson, K. D. Paulsen, and D. W. Roberts, “A spectrally constrained
dual-band normalization technique for protoporphyrin IX quantification in fluorescence-guided surgery,” Opt.
Lett. 37(11), 1817–1819 (2012).
C. Poynton, Digital Video and HDTV (Morgan Kaufmann, 2003), pp. 291–292.
N. Sanai, L. A. Snyder, N. J. Honea, S. W. Coons, J. M. Eschbacher, K. A. Smith, and R. F. Spetzler,
“Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade
gliomas,” J. Neurosurg. 115(4), 740–748 (2011).

#252150
Received 19 Oct 2015; revised 11 Nov 2015; accepted 16 Nov 2015; published 30 Nov 2015
(C) 2015 OSA 1 Dec 2015 | Vol. 6, No. 12 | DOI:10.1364/BOE.6.005063 | BIOMEDICAL OPTICS EXPRESS 5064

33. K. Roessler, A. Becherer, M. Donat, M. Cejna, and I. Zachenhofer, “Intraoperative tissue fluorescence using 5aminolevolinic acid (5-ALA) is more sensitive than contrast MRI or amino acid positron emission tomography
((18)F-FET PET) in glioblastoma surgery,” Neurol. Res. 34(3), 314–317 (2012).

1. Introduction
The goal of neurosurgery in brain tumor management is to maximize the extent of tumor
resection while minimizing functional impairment secondary to surgery. Standard surgical
equipment comprises a white-light neurosurgical microscope and a neuronavigation unit to
guide surgery based on preoperative magnetic resonance imaging (MRI). The use of
preoperative MRI improves the accuracy and safety of surgical resections using spatial coregistration of MRI scans with intraoperative magnified bright-field images taken in real time
during surgery. Indeed, image-guided neurosurgery has increased the completeness of tumor
resection as determined by comparing tumor tissue visible in preoperative relative to
postoperative MRI [1].
More recently, intraoperative fluorescence imaging based on the optical contrast of
molecules such as indocyanine green, fluorescein and protoporphyrin IX (PpIX) has emerged
[2]. PpIX is synthesized and retained preferentially in tumor cells following administration of
the pro-drug 5-aminolevulinic acid (ALA). The biological origin of the optical contrast varies
between fluorophores, each providing different and potentially complementary clinical
information. For example, preferential accumulation of PpIX in tumor cells results in part
from differences in heme biosynthesis and pro-drug uptake. Glioblastoma resection surgery
guided by the red fluorescence of PpIX upon violet light excitation has been demonstrated in
controlled clinical trials to improve the completeness of tumor resection relative to resections
based solely on bright-field, white-light visualization [3].
For the majority of clinical studies of ALA-PpIX guided resection of brain tumors,
fluorescence detection is achieved with a commercial neurosurgical microscope [4]. The
emitted fluorescence is detected by a color RGB camera or by the naked eye through the
oculars of the microscope. The resection is thus guided by subjective visual assessment of the
fluorescence images in real time, referred to as qualitative fluorescence imaging.
Clinical reports have suggested that the metabolic marker PpIX aids in surgical guidance
of other brain pathologies, including meningioma and metastatic brain lesions [5–8]. It has
also been used in other organs for tumor localization and treatment guidance [9]. However,
qualitative fluorescence imaging is intrinsically limited in sensitivity and specificity. The
sensitivity, i.e. the ability to detect (residual) tumor, is hampered by the limited detection
efficiency of CCD cameras (e.g., read-out noise, quantum efficiency), the presence of the
leakage reflectance signals into the detection path (background), and the confounding effects
of intrinsic tissue optical properties [6]. Specificity is negatively impacted by the lack of
spectral resolution when using high-pass interference filtering. Importantly, this limitation
prevents subtraction of tissue auto-fluorescence background, which places a lower limit on
the concentration of the exogenous fluorophore that can be detected and does not allow
simultaneous imaging of multiple fluorophores. Moreover, studies using point fluorescence
measurements combined with diffuse reflectance spectroscopy suggest that low-grade
gliomas also produce diagnostic levels of ALA-induced PpIX but that the signals are too low
to be detected with standard qualitative wide-field fluorescence imaging [6,10]. Patients with
glioblastomas (WHO grade 4 gliomas [11]) do see some survival benefits based on
maximizing extent of resection [12,13] and complete resection is a major factor in preventing
recurrence and improving survival for grade 4 gliomas [14]. Although the specificity of PpIX
uptake in glioblastomas can inhibit the ability to maximize extent of resection, particularly in
areas of edema, providing more sensitive fluorescence imaging can give the surgeon
additional information to make more informed decisions during surgery. Completeness of
resection for low-grade gliomas can considerably extend survival and potentially be curative
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[15–17], motivating the need to improve current fluorescence imaging during brain (and
other) tumor resections [18].
We have previously reported techniques and instruments to circumvent some of the
limitations of qualitative fluorescence imaging. We developed a contact fiberoptic probe
combining fluorescence and diffuse reflectance spectroscopy, allowing for the correction of
light attenuation by the tissue on fluorescence signal and giving absolute PpIX tissue
concentration [19,20]. With a contact fiberoptic probe, we have detected PpIX concentrations
as low as ∼1 ng/ml in brain tissue phantoms under violet light excitation and in clinical in
vivo clinical measurements have shown ALA-PpIX accumulation in low-grade glioma as low
as ~1–10 ng/ml [6,19]. Building upon this work, we then developed a modular, wide-field
spectroscopic imaging system using a scientific CMOS (sCMOS) camera integrated onto an
optical port of a commercial fluorescence neurosurgical microscope [21]. In other work, we
used a CCD-based system for glioblastoma resection in patients, demonstrating that it is able
to detect brain tumor margins beyond what can be detected with qualitative fluorescence
imaging coupled with neuronavigation and MRI [20]. However, when compared with the
contact fiberoptic point probe system, the sensitivity of the both the CMOS and CCD systems
is at least 10 to 20 times less, due primarily to the camera read-out noise [21], compromising
the ability to detect the low levels of ALA-PpIX often present in low-grade gliomas. An
electron-multiplying charge-couple device (EMCCD) allows for fast, high performance signal
detection, particularly for low exposure times or in low-light conditions [22–24], and has seen
use in spectrally resolved fluorescence tomography [25] and fluorescence correlation
spectroscopy [26,27]. In this report we demonstrate that wide-field spectroscopic detection of
PpIX using the state-of-the-art sCMOS system can be further improved with an EMCCD
imaging detector, and that this technology can also be seamlessly integrated into the
neurosurgical workflow.
2. Methods
2.1. System setup
The new fluorescence system is shown in Fig. 1 and consists of custom optical adapters, the
same LCTF as used in the sCMOS system, a coherent fiber-optic imaging bundle (Schott) and
an hNü EMCCD camera (Nüvü Camēras). The custom adapters couple the imaging bundle,
LCTF and camera to an optical port on a commercial neurosurgical microscope (BLUE 400
Pentero, Carl Zeiss Meditec) equipped with a blue light source and fluorescence detection
capabilities.
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Fig. 1. Schematic of the imaging set up used to evaluate the performance of the EMCCD- and
CMOS-based spectral imaging systems connected to different ports on a commercial
neuroscurgical microscope. The photograph shows the EMCCD system, including the coherent
imaging bundle used for remote light detection.

An imaging bundle is required, because the size (15.5 × 15.5 × 17.8 cm) and weight (4.5
kg) of the EMCCD camera prevents it from being directly mounted to the microscope’s
optical port. The 91 cm long bundle comprises a square array (1.6 cm2) of 400 × 400 optical
fibers each of 60 µm core diameter. The LCTF performs single-band filtering (∼7 nm fullwidth at half maximum) in the visible range (400-720 nm) and has a wavelength-dependent
transmittance (maximum 64% at 710 nm and out-of-band rejection ∼4 OD). The EMCCD
camera has 512 × 512 pixels, 92% peak quantum efficiency (QE), effective read-out noise of
<0.1e- at 20 MHz, and a thermal noise D = 0.0002 e-/pixel/s at its lowest cooling temperature
of −85°C. Custom LabView software (National Instruments, Austin, TX) controls data
acquisition, processing and image display. The amplification gain on the EMCCD camera can
be set to values as high as G = 5000 but, unlike the sCMOS system, is affected by an F = 2
excess noise factor induced by the stochastic processes in the electron multiplying register
and by a charge injection noise of C < 0.001 e-/pixel. The EMCCD signal-to-noise ratio
(SNR) is given by [28]
SNR =

QE × ( I PpIX + I Bkg )

σ
F ( I PpIX + I Bkg ) × QE × T + D × T + C  + 2
G
2

2

,

(1)

The same formula applies for the sCMOS camera, and all parameters for both systems are
described in Table 1. For the EMCCD system, the dominant sources of noise are charge
injection noise and to a lesser extent thermal noise. For the sCMOS system, the dominant
sources of noise are readout noise and thermal noise.

#252150
Received 19 Oct 2015; revised 11 Nov 2015; accepted 16 Nov 2015; published 30 Nov 2015
(C) 2015 OSA 1 Dec 2015 | Vol. 6, No. 12 | DOI:10.1364/BOE.6.005063 | BIOMEDICAL OPTICS EXPRESS 5067

Table 1. Descriptions of the parameters used in Eq. (1), with the relevant values for the
EMCCD and sCMOS systems.
Parameter
QE
F
T
D
C
σ
G
IPpIX
IBkg

(I

PpIX

(I

+I

PpIX

Bkg

+I

) × QE

Bkg

) × QE

Description
Quantum efficiency at peak
Excess noise factor induced by the
stochastic process in the electron
multiplying register
Image integration time
Thermal noise
Charge injection noise
Readout noise
Amplification gain
Fluorescence signal from PpIX
Non-specific contributions to the
signal: autofluorescence and ambient
Signal

Shot noise

EMCCD value
92%

2

sCMOS value
60%
1

(varies)
0.0002 e-/pixel/s
< 0.001 e-/pixel
100 e-/pixel
Up to 5000
-

(varies)
0.08 e-/pixel/s
0
1.5 e-/pixel
1
-

-

-

-

-

-

-

2.2. Phantom study
We devised an experimental protocol to compare quantitatively the sensitivity of the
EMCCD- and sCMOS-based systems under identical conditions. As illustrated in Fig. 1, the
systems were simultaneously connected to equivalent optical ports of the neurosurgical
microscope. A power meter was used to verify that the fraction of signal sent to both optical
ports is equal, using the same magnification. The violet light source integrated into the
microscope illuminated tissue-simulating liquid phantoms containing different PpIX
concentrations. The phantoms also contained a lipoprotein suspension (Intralipid) to provide
brain tissue-like scattering coefficients at the excitation wavelength (μs’ = 15-25 cm−1 @ 405
nm) and yellow food coloring (McCormick) as the optical absorber (μa = 20-60 cm−1 @ 405
nm) [29]. Nine sets of phantoms of different absorption-scattering combinations were
prepared, each combination being used with 5 different PpIX concentrations: 5 and 1 μg/ml
and 200, 40 and 8 ng/ml. The optical coefficients at the emission wavelength (600 nm) ranged
from μa = 0.02 to 0.06 cm−1 and μs’ = 8.7 to 14.5 cm−1. Fluorescence images were acquired
simultaneously for each phantom with both cameras for integration times (per wavelength) of
T = 5, 10, 20, 40, and 80 ms. 11 images were acquired from 400 to 430 nm and 41 images
from 600 to 720 nm with 3 nm spectral resolution, for a total of 52 images. The incident
excitation light power density was ∼5 mWcm−2 over a circular field of view of 20 cm2 at a
distance of 30 cm between the microscope condenser lens and the phantom surface.
Spectroscopic reflectance images were also acquired under white-light illumination.
Quantitative fluorescence values were computed using previously-reported algorithms [20,30]
in which the raw fluorescence spectra are normalized with the reflectance spectra to account
for the spectral distortion caused by tissue absorption and scattering. Spectral un-mixing was
used to separate the contribution of PpIX from background signal including intrinsic
fluorescence, using a nonnegative least-squares approach [19,20]. As described previously
[20,30], a calibration factor was determined from a PpIX dilution experiment that related the
attenuation-corrected spectra to actual dye concentrations. This procedure produced an
estimate of PpIX concentration at the tissue surface (in μg/ml) for each image pixel.
2.3. Ex vivo tissue study
To test the utility of performing fluorescence imaging enabled by the EMCCD, two female
Lewis rats (Charles River, QC, Canada) were used under institutional approval (University
Health Network, Toronto, Canada). For tumor induction, the rats were placed under 4%
isoflurane anesthesia (oxygen flow at 2 L/min), induced in a chamber and sustained by 1-
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2.5% isoflurane at 1 L/min via a rat-adapted nose cone. The eyes were lubricated with tear
gel, and the animals were placed on a warming blanket. For each rat, the scalp was shaved
and disinfected with betadine and isopropanol, followed by a 1.5 cm incision along the
midline. A 1 mm burr hole was made in the left hemisphere, 3 mm posterior to the bregma
and 2 mm to the left of the sagittal suture, exposing the dura but leaving it intact. Subsurface
intracranial brain tumors were induced by injection of 105 RG2 (ATCC CRL-2433) cells in 5
µL of RPMI-1640 media (Sigma-Aldrich) through the burr hole, at a depth of 2 mm below
the dura using a 26G Hamilton syringe. Tumors were allowed to grow for 14 days to a size of
3-4 mm. On the day of surgery, 120 mg/kg of ALA (Sigma-Aldrich) was injected
intraperitoneally. Four hours post-injection, each rat was sacrificed; the whole brain was
removed intact and sectioned into 3-4 mm thick slices under subdued light. The brain sections
were mounted on a tissue cassette and were then frozen in liquid nitrogen/isopentane.
On the day of imaging, the tissue samples were slowly thawed to room temperature. For
each of the 7 tissue samples (3 from one animal and 4 from the other), a sequence of
spectroscopic fluorescence and diffuse reflectance images were acquired using the EMCCD
from 400 to 430 nm and 600-720 nm with 3 nm spectral resolution. Fluorescence and whitelight images were also acquired using the clinical Zeiss Pentero surgical microscope equipped
with a 400 nm excitation fluorescence imaging option. The exposure time with the EMCCD
varied from 10 to 100 ms with a gain of 500. Background images were also taken with no
excitation light. Each sample lying on one side of the tissue cassette was placed at the same
position in a box made to isolate the sample from ambient light sources. The sample was
retained in the cassette to keep it intact. The fluorescence spectra were normalized using the
reflectance spectra to account for the effects of tissue absorption and scattering, and spectral
un-mixing was applied to separate the contribution of the fluorophore from background
signals including tissue autofluorescence, based on the acquired background images with no
excitation light [19,20]. A hand-held optical probe was used to measure fluorescence in the
tissue slices. The probe, described previously [19,29], has optical fibers for fluorescence
excitation at 405 nm, and spectroscopic detection between 430 and 750 nm. The diffuse
reflectance spectra at two different source-detector fiber separations is also measured and
used to derive the tissue absorption and scattering properties that are then applied to the
measured fluorescence spectrum to derive the absolute fluorophore concentration in the
tissue. For each slice, the probe was placed in contact with the tissue specimen to measure
fluorescence at a single location. The measurement locations for the probe were chosen as
positions with high fluorescence observed on the standard qualitative fluorescence image.
3. Results
3.1. Phantom study
Figure 2 shows the fluorescence imaging estimates of PpIX concentration as a function of the
true values in the phantoms for the two systems using different exposure times. The
calibration factor allows the x and y axis to be expressed in the same units (μg/ml), while the
attenuation correction factor brings the data points closer together along the y-axis [30].
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Fig. 2. Recovered values of PpIX concentration versus the known PpIX values in the different
tissue-simulating phantoms for both the CMOS (a,c) and EMCCD systems (b,d) with
integration times of 5 ms per wavelength (a,b) and 20 ms per wavelength (c,d). Measurements
were averaged over a 5 by 5 pixel window in the center of the inclusion. Measurements at each
PpIX concentration correspond to 9 phantoms with different absorption-scattering
combinations at 600 nm ranging from μa = 0.02 to 0.06 cm−1 and μs’ = 8.7 to 14.5 cm−1. The
lines of fit are in red.

These plots indicate that the quantified fluorescence varies linearly with concentration to
the lowest PpIX level (8 ng/ml) for the EMCCD system, but the linearity breaks down at
around 40 ng/ml for the sCMOS system at a 20 ms exposure time (no significant linearity
observed for a 5 ms exposure time, see below for discussion of the linearity at different
exposure times). Thus, since the noise floor of the EMCCD system was not reached at the
lowest concentration, its sensitivity is at least 1-2 orders of magnitude greater than that of the
sCMOS system, which is the current state-of-the-art for ALA-PpIX fluorescence detection in
neurosurgical guidance. In fact, the sensitivity is comparable to that of the point probe that
has a PpIX detection limit ∼1 ng/ml. The R2 values for the fit of estimated vs. true PpIX
concentration, for the CMOS and EMCCD systems and for each exposure time, are listed in
Table 2. These quantities were computed based on the residuals for the linear fit of all points
for a particular exposure time (i.e. the values for all phantoms at all concentrations for one
exposure time yield a single R2 value). The R2 values for the EMCCD system are 0.89 or
greater for all exposure times, while those for the CMOS system range from 0.64 to 0.79 for
exposure times less than 40 ms, demonstrating the improved sensitivity of the EMCCD
system for fluorescence detection, particularly at lower fluorophore concentrations and for
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lower exposure times. The R2 value for an 80 ms exposure time is somewhat greater for the
CMOS system.
Table 2. R2 values for the fit of quantified PpIX concentration (log) vs true PpIX
concentration (log) for the CMOS and EMCCD systems at different exposure times.
Exposure
time (ms)
5
10
20
40
80

R2 for CMOS
quantification (a.u.)
0.64
0.69
0.79
0.92
0.95

R2 for EMCCD
quantification (a.u.)
0.89
0.91
0.93
0.93
0.92

Limitations of the sCMOS system sensitivity are further illustrated in the spectra of Fig. 3,
in which the 635 nm PpIX emission peak cannot be detected even at 40 ng/ml concentration
for 20 ms exposure time. The PpIX emission peak is not visible with the CMOS system for
exposure times of 5, 10 and 40 ms (data not shown), whereas the peak is visible for all
exposure times with the EMCCD system. The increased EMCCD system sensitivity is
directly related to its multiplication gain that, as shown in Eq. (1), attenuates the read-out
noise.

Fig. 3. Examples of fluorescence spectra acquired with both imaging systems for 20 ms
exposure at PpIX concentrations of 40 and 200 ng/ml and with optical properites μa = 0.03
cm−1 and μs’ = 14.5 cm−1. The measurements were averaged over a 5 by 5 pixel window at the
center of the inclusion, and the spectra are normalized by reflectance data.

The results presented here suggest that the excess noise factor, F, and the injection charge
noise, C, do not meaningfully affect the EMCCD’s detection sensitivity under experimental
conditions relevant to its intended clinical use. However, larger values of C, as found in other
EMCCD camera models, could negatively impact performance for PpIX detection.
3.2. Ex vivo tissue study
Figure 4 shows images of tissue samples acquired using the surgical microscope’s internal
RGB camera (TRIO 630 integrated camera system for the Pentero microscope) and the
fluorescence images acquired with the EMCCD system. In each sample, two areas identified
by boxes 1 and 2, compare the recovered contrast of the EMCCD system with the visible
contrast attained through the qualitative fluorescence imaging feature available on the Pentero
microscope. Contrast ratio (CR) was calculated as the ratio of intensity in box 1 or 2 to the
intensity in the background box shown in Fig. 4. The background box was selected as an area
of tissue where negligible fluorescence was observed.
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Fig. 4. (a,c) Two ex vivo brain tissue samples containing glioma, as viewed through the
neurosurgical microscope under violet light excitation. (b,d) show the corresponding images
for the derived quantitative fluorescence using the EMCCD system. Representative contrast
ratios (CR) are shown within the tumor. The images have been cropped to highlight the tissue
samples.

For the EMCCD, the intensity represents the recovered fluorescence value (as described
in Materials and Methods). For the microscope, the intensity Im from the surgical
microscope’s internal RGB camera was calculated as the luminance [31] in order to represent
the visibility of each color component in the fluorescent image:
Im =

299 R + 587G + 114 B
1000

(2)

where red (R), green (G) and blue (B) correspond to the intensity values of the corresponding
color components in the broadband image. Luminance was used in order to quantify the
visual contrast observed by the human eye in the RGB image from the surgical microscope,
since it is the current standard used by neurosurgeons for assessing the presence of
fluorescence. It may be possible to optimize a camera setup for better contrast detection of
fluorescence by selecting appropriate spectral detection bands, however the RGB camera used
is from a commercial neurosurgical microscope for fluorescence-guided surgery, and so this
represents the standard for comparison. For both tissue samples, the EMCCD fluorescence
results in greater contrast ratios than the visible fluorescence obtained through the
neurosurgical microscope in areas of high (box 1 in both images) as well as less visible
fluorescence (box 2 in both images). The fiberoptic contact probe was used to measure a
single location on each tissue sample corresponding to a location of high visible fluorescence
on the microscope image, and the measured fluorescence from the probe was compared with
the fluorescence recovered in a 5 by 5 pixel window at the same location in the EMCCD
image (Fig. 5).
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Fig. 5. Correlation between the quantatitive PpIX fluorescence measured with the EMCCD
system at 7 different locations (averaged over 5 by 5 pixel regions) and the corresponding
quantitative point probe measurements. The linear regression line is also shown.

There is good correlation between the EMCCD and probe data (R2 = 0.87), which allows
the EMCCD thresholds in Section 3.A to be compared directly with the detection capabilities
of the probe. The probe can detect PpIX concentrations as low as 1 ng/ml in vivo. Hence,
since the EMCCD system (i) can detect as little as 8 ng/ml PpIX in phantoms, (ii)
demonstrates linearity in fluorescence quantification for a range of concentrations and optical
properties for exposure times as low as 5 ms, and (iii) shows strong correlation with the probe
for fluorescence detection, indicating its detection capabilities are comparable to the highly
sensitive point probe system, the clinical value of which has already been proven in high and
low-grade glioma surgery [29].
4. Discussion
We have demonstrated that a spectroscopic EMCCD-based imaging system out-performs the
state-of-the-art sCMOS-based imaging system currently used in ALA-PpIX fluorescenceguided tumor resection. Its higher detection sensitivity translates directly into an ability to
detect substantially lower ALA-PpIX concentrations. As demonstrated in clinical studies to
date, reliable detection of lower fluorophore concentrations should translate into improved
completeness of tumor resection, particularly in quantitative fluorescence imaging mode
where the confounding effects of variable light attenuation by the tissue are minimized
[6,20,32,33]. The increase in wide-field detection sensitivity can be achieved despite the
added light losses (estimated ∼30%) from the imaging bundle between the camera and the
microscope. The presence of non-specific signals from tissue autofluorescence and ambient
light can limit the benefits associated with the enhanced sensitivity provided by EMCCD
detection during surgical interventions. However, ambient light is minimized during
fluorescence-guided surgeries and our clinical measurements with the probe system to date
indicate that the autofluorescence intensity is considerably smaller than the PpIX emissions
associated with gliomas [29]. Furthermore, the ex vivo tissue results demonstrate that the
EMCCD system has improved fluorescence detection sensitivity under these conditions.
Perhaps the most important finding in the phantom study is that wide-field fluorescence
quantification can potentially achieve a level of sensitivity comparable to that obtained with a
state-of-the-art quantitative point contact probe that is currently being used to guide glioma
resection in clinical trials [20]. The lowest concentrations of PpIX (8 ng/ml) detected here are
consistent with the concentrations found in low-grade gliomas using a clinically-validated
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quantitative fluorescence-reflectance fiberoptic probe [6,10]. This indicates that the level of
improved sensitivity for the EMCCD system is relevant for low-grade glioma surgery,
especially since the noise floor of the system has not yet been reached at these concentrations.
The EMCCD-based system performance will be tested in future studies in patients
undergoing ALA-induced fluorescence-guided glioma resection. The ability to generate widefield images with the same level of disease detection sensitivity as currently achievable only
in point-by-point mode is an important advantage in clinical practice.
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